Technical Analysis for FOLD - Amicus Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 8.37 -0.83% -0.07
FOLD closed down 0.83 percent on Wednesday, October 23, 2019, on 60 percent of normal volume.

Earnings due: Nov 12

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical FOLD trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup -0.83%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.83%
Narrow Range Bar Range Contraction -0.83%
NR7 Range Contraction -0.83%
Crossed Above 20 DMA Bullish 1.09%
20 DMA Resistance Bearish 3.02%
Doji - Bearish? Reversal 3.02%
Outside Day Range Expansion 3.02%

Older signals for FOLD ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.
Medicine Biopharmaceutical Rare Diseases Inborn Errors Of Metabolism Orphan Drugs Enzyme Replacement Therapy Pompe Disease Fabry Disease Gaucher Disease Lipid Storage Disorders Lysosomal Storage Disorders Protein Folding Treatment Of Pompe Disease
Is FOLD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.61
52 Week Low 7.11
Average Volume 3,702,402
200-Day Moving Average 11.6111
50-Day Moving Average 9.074
20-Day Moving Average 8.0603
10-Day Moving Average 8.122
Average True Range 0.4062
ADX 37.95
+DI 16.199
-DI 20.1938
Chandelier Exit (Long, 3 ATRs ) 7.9714
Chandelier Exit (Short, 3 ATRs ) 8.3286
Upper Bollinger Band 8.6502
Lower Bollinger Band 7.4704
Percent B (%b) 0.76
BandWidth 14.637172
MACD Line -0.2523
MACD Signal Line -0.3901
MACD Histogram 0.1377
Fundamentals Value
Market Cap 1.38 Billion
Num Shares 165 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -5.69
Price-to-Sales 135.92
Price-to-Book 7.22
PEG Ratio -0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.73
Resistance 3 (R3) 8.76 8.67 8.67
Resistance 2 (R2) 8.67 8.58 8.66 8.65
Resistance 1 (R1) 8.52 8.52 8.48 8.49 8.63
Pivot Point 8.43 8.43 8.41 8.42 8.43
Support 1 (S1) 8.28 8.34 8.24 8.25 8.11
Support 2 (S2) 8.19 8.28 8.18 8.09
Support 3 (S3) 8.04 8.19 8.07
Support 4 (S4) 8.01